within Pharmacolibrary.Drugs.ATC.R;

model R06AD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AD01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Alimemazine (also known as trimeprazine) is a first-generation antihistamine and phenothiazine derivative used primarily for its sedative and anti-allergic properties. It has been used for symptomatic relief of allergy, pruritus, and as a sedative, especially in pediatric settings; however, its use has declined and in several countries it is not commonly approved or prescribed today due to side effects and availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects based on secondary sources, as no primary PK studies with full compartmental model details are available in scientific literature.</p><h4>References</h4><ol><li><p>Sponheim, S, et al., &amp; Mørland, J (1990). Pharmacokinetics of trimeprazine in children. <i>Pharmacology &amp; toxicology</i> 67(3) 243–245. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0773.1990.tb00821.x&quot;>10.1111/j.1600-0773.1990.tb00821.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2255680/&quot;>https://pubmed.ncbi.nlm.nih.gov/2255680</a></p></li><li><p>McKay, G, et al., &amp; Midha, KK (1984). Radioimmunoassay for trimeprazine in human plasma. <i>Journal of pharmacological methods</i> 12(3) 203–211. DOI:<a href=&quot;https://doi.org/10.1016/0160-5402(84)90061-5&quot;>10.1016/0160-5402(84)90061-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6536824/&quot;>https://pubmed.ncbi.nlm.nih.gov/6536824</a></p></li><li><p>Dumortier, G, et al., &amp; Degrassat, K (2005). [Prescription of psychotropic drugs in paediatry: approved indications and therapeutic perspectives]. <i>L&#x27;Encephale</i> 31(4 Pt 1) 477–489. DOI:<a href=&quot;https://doi.org/10.1016/s0013-7006(05)82409-1&quot;>10.1016/s0013-7006(05)82409-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16389715/&quot;>https://pubmed.ncbi.nlm.nih.gov/16389715</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AD01;
